Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.49 |
| ▸ | MMP13 | P45452 | 10/20 | 0.49 |
| ▸ | MMP9 | P14780 | 6/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.41 |
| ▸ | MMP3 | P08254 | 4/20 | 0.39 |
| ▸ | MMP7 | P09237 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21035598 | 0.90 | MMP1 (0.43) | MMP1MMP13MMP9EPHX2ADAM17 | |
| SCHEMBL21035070 | 0.90 | MMP1 (0.43) | MMP1MMP13MMP9EPHX2ADAM17 | |
| SCHEMBL21035503 | 0.88 | EPHX2 (0.39) | MMP1MMP13MMP9EPHX2ADAM17 | |
| SCHEMBL21036264 | 0.84 | MMP1 (0.47) | MMP1MMP13MMP9EPHX2MMP3 | |
| SCHEMBL21035636 | 0.84 | GPR119 (0.39) | MMP1MMP13MMP9EPHX2ADAM17 | |
| SCHEMBL21034960 | 0.83 | GPR119 (0.40) | MMP1MMP13MMP9EPHX2ADAM17 | |
| SCHEMBL21035570 | 0.82 | MMP1 (0.40) | MMP1MMP13MMP9ADAM17MMP3 | |
| SCHEMBL21035368 | 0.82 | ACACB (0.38) | MMP1MMP13MMP9EPHX2ADAM17 | |
| SCHEMBL21036251 | 0.82 | ACACB (0.38) | MMP1MMP13MMP9EPHX2ADAM17 | |
| SCHEMBL21035075 | 0.81 | MMP13 (0.45) | MMP1MMP13MMP9ADAM17MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019104011-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-31 | — | — | WO | disclosed |